Mediquest Therapeutics, a Bothell, WA-based developer of topical treatments for inflammatory diseases, has sold $2.3 million of a $15 million equity offering according to a filing made today with the U.S. Securities and Exchange Commission. Founded in 1994, the company is developing a treatment for Raynaud’s disease, a condition that causes numbness in the fingers and toes when exposed to cold temperatures. The company’s application for FDA approval was turned down last fall, and it is trying again.